AI/ML for drug discovery

Seeking Strategic Partnerships

Spektron Systems seeks a few, select strategic partners with which to demonstrate, and share in the value of, Q-MAP’s powerful, AI-based Drug Discovery capacity.  Spektron desires to succeed in demonstrations of:

  • Quantitative High Throughput Screen Data Analysis
  • Predictive Toxicity modeling and off-target identification
  • ID of candidates for drug repurposing

About us

AI-based Drug Design

End-to-end In Silico Drug Design

Extending our collaborative work with the National Center for Toxicological Research, Spektron Systems has developed a platform for AI-assisted drug design – Q-MAP™.
 

The platform takes a many-models approach to reduce uncertainty in predictions for clinical results. The Q-MAP platform shortens discovery timelines from biology to preclinical candidates (PCC) from 4.5+ years to approximately 1 year.  Our approach disruptively improves pharmaceutical pipeline success.

qHTS Data Analysis

Qualitative data meets Quantum data

Q-MAP™ combines modern methods of machine learning and computational chemistry.

 

Spektron have developed predictive models for virtual screening of molecules on a variety of endpoints toxicity, efficacy, and side-effects.  This ability to screen molecules in-silico is available for Spektron’s drug discovery pipeline as well as for our partners.

News

Events
Spektron Systems

Spektron Systems in NYC panel at BIO CEO Summit

Dr. David Wolf will be speaking on a panel presentation about AI in Healthcare and Spektron’s unique approach to medicinal molecule design. This invite-only presentation will be attended by investors looking to learn more about AI in this industry. Hosted by IMPACTIVE BioConsult, this presentation appends the 2019 BIO CEO SUMMIT and is being held 7:00 pm at Morgan Stanley.

Read More »
News
Spektron Systems

Dr. Wolf backstage at a Beryl Elites Investor Conference

Dr. David Wolf, the President and Chief Medical Officer for Spektron Systems, sat on the panel with other distinguished speakers talking about Artificial Intelligence. In this backstage interview clip, he about the revolutionary impact that AI is having in many industries. He addresses one of the key components of any good machine learning implementation – “Curation! Curation! Curation!”

Read More »
News
Jessica Heidrich

Welcome Iva!

We would like to give a big welcome to Iva for joining Spektron full time! Iva is one of our Computational Chemists and a great

Read More »
News
Tim Dockins

Exploring Charles River Laboratories

Spektron Systems has actively engaged in developing synthesis and test plans on five representative molecules representing designs for an antipsychotic medication. Primarily for the purposes

Read More »

The Team

Robert Cain

EVP / Chief Strategy Officer

Robert Cain

Robert Cain is an MBA with background in investment banking, IPOs and pharmaceuticals, and experience in strategy, finance and business development for companies ranging from startups to Fortune 500. He holds a B.A. from Harvard and an MBA from The Wharton School of the University of Pennsylvania.

Tim Dockins

Chief Operating Officer

Tim Dockins

Tim Dockins is a polyglot programmer with an emphasis on complex data manipulation and visualization. He has an extensive background in several specialty areas including predictive modeling, machine learning and pattern classification, UI design and implementation, data science, and program management. Tim received a B.S. in Computer Science from the University of Texas at Arlington. He is a Ph.D. Candidate in the Computer Science and Engineering department at the same university where he studies intelligent systems and machine learning.

Bob D'Agostino, M.Sc.

Director, Machine Learning

Bob D'Agostino

Bob D'Agostino leads the ML/AI platform development. He has over 15 years of experience leading/implementing scientific computing projects for a variety of industries and applications, including drug discovery, defense, chemical detection, semiconductors, and the automotive industry. He has a B.S. in Physics from Syracuse University and an M.S. in Applied Mathematics from the University of Massachusetts Lowell.

W. Ken Fang, Ph.D.

Senior Vice President for Drug Discovery

W. Ken Fang, Ph.D.

A research scientist with over 20 years of experience of designing new innovative drugs for treating neuropathic pain, CNS diseases, inflammation, ocular and skin diseases. Dr. Fang has comprehensive expertise in small molecule HTS hit identification, lead generation, and optimization based on target selectivity, ADME, toxicology, preclinical safety, and in vivo pharmacology. He has extensive experience in parallel synthesis techniques, and broad experience in preparation of patent applications and publication manuscripts with over 52 patents.

Ashley Meyer, M.Sc.

Principal Informatics Scientist

Ashley Meyer, M.Sc.

Ashley Meyer acquired her B.S. in Biology from the University of Arkansas at Little Rock (UALR), and her M.S. in Biology with an emphasis in Evolutionary Ecology from the University of Louisiana at Monroe (ULM). Her varied specialties include bacterial culturing and testing, radio telemetry, transmitter and PIT tagging, and collection and curation of morphometric data for invertebrates. Meyer served as an instructor of Microbiology and Human Anatomy and Physiology at ULM and Pulaski Technical College.

Max Sharifi, Ph.D.

Principal Computational Chemist

Max Sharifi, Ph.D.

As a Principal Computation Chemist, Dr. Sharifi leads computational modeling and molecular design operations at Spektron. His expertise is in developing computational models of efficacy and toxicity models using a variety of machine learning techniques. He works closely with Medicinal chemists and pharmacologists to utilize Spektron’s Q-MAP platform to develop computational chemistry-driven decision-making for molecular generation.
AshleyFlory

Ashley Flory, M.Sc.

Senior Informatics Scientist

Ashley Flory, M.SC.

Ashley acquired her B.S. in Forensic Chemistry from the Arkansas State University (ASU) and her M.S. in Biology. As an Informatics Scientist, Ashley Flory is responsible for researching, annotating, and otherwise curating data for training machine learning models. She draws upon her background in biology research to lead the team in exploring new areas for translational studies.

Iva Stoyanova-Slavova, Ph.D.

Principal Computational Chemist

Iva Stoyanova-Slavova, Ph.D.

As a principal computational chemist, Iva is responsible for computational modeling on various activity endpoints including human-level toxicities and efficacies. She works directly with machine learning experts to develop tools for discovering toxicophores and pharmacophores. Dr. Slavova’s expertise makes her a leader in developing the processes and technologies utilized at Spektron.

Jessica Heidrich, B.SC.

Executive Administrative Assistant

Jessica Heidrich, B.SC.

Ms. Heidrich is both executive assistant, personnel/human resource manager, as well as administrative lead for accounts payable, payroll, and other duties. Additionally, Jessica works with the informatics team conducting data curation and research alongside Ashley Meyer and Ashley Flory.

Contact Us

Mailing Address
417 Main St
Little Rock, AR 72201
(800) 972-0751

Visit us on LinkedIn or follow us on Twitter!